Basel, 28 March 2025: Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto^® (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castr......
View Details

Related News

• Dissolution Test is Minor Defect, when Active Content is Within Limit, does not Warrant Prosecution: Rajasthan HC (03-04-2025)

---

• Tripura DCA finds no proof of selling substandard injection by Elder Prroject and Elder Pharmaceuticals (03-04-2025)

---

• AP government’s crackdown on sale of banned drugs intensifies (03-04-2025)

---

• Fake pharmacy registration racket busted in Delhi, Council ex-registrar among 47 held (03-04-2025)

---

• RGHS scam: FIR against 3 in Bharatpur; loss to government exchequer due to high-value transactions (02-04-2025)

---

• CDSCO issues Cardio, Neuro device revised classification draft (02-04-2025)

---

• Gujarat FDCA buys 25 advanced handheld spectrophotometers (02-04-2025)

---

• Investigation Into Spurious Medicines Ongoing, Court Hearing in May: Tripura CM (02-04-2025)

---

• WHO issues its first-ever reports on tests and treatments for invasive fungal diseases (01-04-2025)

---

• 3 companies fail to prove 'skin whitening' claims, fined (01-04-2025)

---